For people in Saudi Arabia with a rare inherited form of very high cholesterol, taking a drug called Evolocumab once a month didn’t seem to lower their bad cholesterol much — the drop was small and...

Pro

Against

Evidence from Studies

Supporting (1)

Community contributions welcome

Effectiveness of PCSK9 inhibitors in homozygous familial hypercholesterolemia: insights from a Saudi Arabia genetic population

Cohort Study

Human

Contradicting (0)

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Effectiveness of PCSK9 inhibitors in homozygous familial hypercholesterolemia: insights from a Saudi Arabia genetic population

Score: 27

DOI: 10.1093/eurjpc/zwaf236.442

Similar Assertions

For people in Saudi Arabia with a rare genetic form of very high cholesterol, taking a drug called evolocumab every two weeks seems to lower their bad cholesterol a little bit — not a huge drop, but enough to show it's doing something.

90%

In a group of 37 people in Saudi Arabia with a rare cholesterol condition, the most common gene change was in the LDL receptor, which likely breaks how the body clears bad cholesterol — and this might be common there.

73%

People in Saudi Arabia with a rare cholesterol condition don’t seem to lower their bad cholesterol as much with a certain drug as other people did in past studies — and it might be because of their genes or how the treatment is used in real clinics.

70%